Projet PIPgen (Horizon 2020, appel à projets 2020)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

There are more than 7000 rare diseases, affecting approximately 30 million European Union citizens. Eighty percent of rare diseases have monogenic origin and are often chronic or life-threatening. Several of these genetic mutations are also implicated in cancer, a disease of epidemic proportions (>14 million new cases/year worldwide). Genetic alterations in the PI3K/PTEN pathway are common events in both monogenic rare diseases and in cancer. Despite the molecular commonalities, these two pathologies have predominantly been investigated as independent entities. We aim to take advantage of the knowledge that has been generated regarding the role of PI3K in cancer to better understand the recently-discovered PI3K-related rare diseases (overgrowth syndromes, primary immunodeficiencies and cognitive deficiencies). Conversely, discoveries emanating from PI3K-related rare diseases will impact in the understanding of cancer. Ultimately, this cross-fertilization will impact on the clinical strategies to treat both rare diseases and cancer. Our network, under the acronym of PIPgen, aims to (1) produce the next generation of scientists that can navigate with ease between academic, industrial and clinical sectors and have the scientific and softs skills to convert research findings into commercialization and clinical applications, and (2) generate innovative knowledge that can be translated to the diagnosis and treatment of both rare diseases and cancer. This network provides a pan-European interdisciplinary and intersectorial training program of excellence bringing young researchers together with world leading academics, clinicians, entrepreneurs with experience from the pharma industry, corporate research as well as with dissemination and outreach activities. PIPgen has been conceived to make a real therapeutic impact both in rare diseases and cancer, based on basic bioscience.

Mots clés : pi3k, rare diseases, cancer, signalling, pros, phts, apds

Participants :
- CIC bioGUNE (Espagne) — Partner, beneficiary, Recherche, subvention : 250904.88 €
- University of Cambridge (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 606345.12 €
- Erasmus MC (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 265619.88 €
- Amsterdam University Medical Centers (Pays-Bas) — Partner, beneficiary, Recherche, subvention : 265619.88 €
- Kither biotech srl (Italie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 261499.68 €
- Université Paris Cité (France) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 274802.04 €
- Fundación Josep Carreras Contra la Leucemia (Espagne) — Coordinator, beneficiary, Recherche, subvention : 501809.76 €
- Quantitative genomic medicine laboratories sl (Espagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 250904.88 €
- Institut national de la santé et de la recherche médicale (France) — Partner, beneficiary, Recherche, subvention : 549604.08 €
- Radboud University Nijmegen Medical Centre (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 265619.88 €
- University of London (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 606345.12 €